Eris Lifesciences Limited (ERIS) — Cash Flow-to-Debt Ratio
Eris Lifesciences Limited (ERIS) has a Cash Flow-to-Debt Ratio of 0.07x as of September 2025, meaning its operating cash flow of Rs2.39 Billion could theoretically repay 0% of its total liabilities (Rs36.56 Billion) in one year. See ERIS financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Eris Lifesciences Limited Cash Flow-to-Debt Ratio (2012–2026)
Historical debt coverage capacity for Eris Lifesciences Limited across 15 annual periods. For the full cash flow conversion analysis, see ERIS operating cash flow.
Annual Cash Flow-to-Debt Ratio for Eris Lifesciences Limited (2012–2026)
Year-by-year debt coverage analysis for Eris Lifesciences Limited. Check ERIS cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (INR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2026 | 0.10x | Rs3.47 Billion | Rs34.70 Billion | ▼ -64.7% |
| 2025 | 0.28x | Rs10.65 Billion | Rs37.61 Billion | ▲ +122.9% |
| 2024 | 0.13x | Rs4.86 Billion | Rs38.27 Billion | ▼ -37.0% |
| 2023 | 0.20x | Rs2.92 Billion | Rs14.47 Billion | ▼ -80.6% |
| 2022 | 1.04x | Rs3.78 Billion | Rs3.64 Billion | ▼ -28.5% |
| 2021 | 1.45x | Rs3.75 Billion | Rs2.58 Billion | ▲ +37.2% |
| 2020 | 1.06x | Rs2.71 Billion | Rs2.56 Billion | ▲ +82.8% |
| 2019 | 0.58x | Rs2.23 Billion | Rs3.85 Billion | ▲ +41.8% |
| 2018 | 0.41x | Rs2.35 Billion | Rs5.74 Billion | ▼ -79.3% |
| 2017 | 1.98x | Rs2.00 Billion | Rs1.01 Billion | ▲ +42.2% |
| 2016 | 1.39x | Rs1.31 Billion | Rs945.34 Million | ▲ +35.4% |
| 2015 | 1.03x | Rs900.57 Million | Rs876.95 Million | ▲ +2.8% |
| 2014 | 1.00x | Rs896.24 Million | Rs897.40 Million | ▲ +60.2% |
| 2013 | 0.62x | Rs380.15 Million | Rs609.72 Million | ▲ +1.1% |
| 2012 | 0.62x | Rs302.99 Million | Rs491.55 Million | — |